Peijia Medical Crecimiento futuro

Future controles de criterios 2/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Peijia Medical de 61.5% y 29% por año respectivamente. Se prevé que el BPA crezca en un 61.3% al año. Se espera que la rentabilidad financiera sea de -2.9% en 3 años.

Información clave

61.5%

Tasa de crecimiento de los beneficios

61.3%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Medical Equipment	40.1%
Tasa de crecimiento de los ingresos	29.0%
Rentabilidad financiera futura	-2.9%
Cobertura de analistas	Low
Última actualización	11 Sep 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Why Investors Shouldn't Be Surprised By Peijia Medical Limited's (HKG:9996) 26% Share Price Surge

Sep 09

Risks Still Elevated At These Prices As Peijia Medical Limited (HKG:9996) Shares Dive 30%

Jul 17

More Unpleasant Surprises Could Be In Store For Peijia Medical Limited's (HKG:9996) Shares After Tumbling 27%

Mar 28

More Unpleasant Surprises Could Be In Store For Peijia Medical Limited's (HKG:9996) Shares After Tumbling 29%

Jan 22

Despite Lacking Profits Peijia Medical (HKG:9996) Seems To Be On Top Of Its Debt

Oct 05

A Look At The Fair Value Of Peijia Medical Limited (HKG:9996)

Aug 29

We're Hopeful That Peijia Medical (HKG:9996) Will Use Its Cash Wisely

Mar 16

We Think Peijia Medical (HKG:9996) Can Easily Afford To Drive Business Growth

Nov 26

We're Hopeful That Peijia Medical (HKG:9996) Will Use Its Cash Wisely

Jul 30

Is Peijia Medical Limited (HKG:9996) Worth HK$28.3 Based On Its Intrinsic Value?

May 05

Could The Peijia Medical Limited (HKG:9996) Ownership Structure Tell Us Something Useful?

Mar 03

Peijia Medical Limited's (HKG:9996) Intrinsic Value Is Potentially 43% Above Its Share Price

Jan 27

We Think Peijia Medical (HKG:9996) Can Afford To Drive Business Growth

Dec 23

Previsiones de crecimiento de beneficios e ingresos

SEHK:9996 - Estimaciones futuras de los analistas y datos financieros pasados (CNY Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	1,021	-30	-28	42	4
12/31/2025	814	-102	-131	-33	4
12/31/2024	622	-176	-169	-94	4
6/30/2024	517	-252	-305	-155	N/A
3/31/2024	479	-322	-602	-369	N/A
12/31/2023	441	-393	-900	-583	N/A
9/30/2023	399	-460	-921	-609	N/A
6/30/2023	357	-528	-942	-635	N/A
3/31/2023	304	-468	-760	-506	N/A
12/31/2022	251	-408	-579	-376	N/A
9/30/2022	227	-449	-684	-441	N/A
6/30/2022	204	-491	-790	-506	N/A
3/31/2022	170	-533	-710	-471	N/A
12/31/2021	137	-574	-629	-436	N/A
9/30/2021	106	-515	-446	-327	N/A
6/30/2021	76	-455	-262	-217	N/A
3/31/2021	57	-1,262	-235	-199	N/A
12/31/2020	39	-2,069	-207	-181	N/A
9/30/2020	33	-2,128	-203	-180	N/A
6/30/2020	28	-2,187	-200	-179	N/A
3/31/2020	23	-1,360	-158	-141	N/A
12/31/2019	19	-532	-116	-103	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que 9996 siga sin ser rentable en los próximos 3 años.

Beneficios vs. Mercado: Se prevé que 9996 siga sin ser rentable en los próximos 3 años.

Beneficios de alto crecimiento: Se prevé que 9996 siga sin ser rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (29% al año) de 9996 crezcan más rápidamente que los del mercado Hong Kong (7.8% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos (29% al año) de 9996 crezcan más rápidamente que un 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: 9996 se prevé que no sea rentable en 3 años.

Peijia Medical Crecimiento futuro

Future controles de criterios 2/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Consensus EPS estimates upgraded to CN¥0.29 loss

Forecast to breakeven in 2025

Forecast to breakeven in 2025

Peijia Medical Limited Provides Unaudited Revenue Guidance for the Period from January 1, 2023 to June 30, 2023

Forecast to breakeven in 2025

Consensus EPS estimates fall by 73%

Recent updates

Peijia Medical Limited Announces Resignation of Yu Zhiyun as Non-Executive Director and A Member of the Board's Remuneration Committee

First half 2024 earnings released: CN¥0.10 loss per share (vs CN¥0.31 loss in 1H 2023)

Why Investors Shouldn't Be Surprised By Peijia Medical Limited's (HKG:9996) 26% Share Price Surge

Peijia Medical Limited, Annual General Meeting, Sep 30, 2024

Consensus EPS estimates upgraded to CN¥0.29 loss

First half 2024 earnings released: CN¥0.10 loss per share (vs CN¥0.31 loss in 1H 2023)

Peijia Medical Limited to Report First Half, 2024 Results on Aug 23, 2024

Risks Still Elevated At These Prices As Peijia Medical Limited (HKG:9996) Shares Dive 30%

Full year 2023 earnings: EPS and revenues miss analyst expectations

Less than half of directors are independent

Peijia Medical Limited to Report Fiscal Year 2023 Results on Jun 15, 2024

Full year 2023 earnings: EPS and revenues miss analyst expectations

More Unpleasant Surprises Could Be In Store For Peijia Medical Limited's (HKG:9996) Shares After Tumbling 27%

Peijia Medical Limited to Report Fiscal Year 2023 Results on Mar 28, 2024

Forecast to breakeven in 2025

Peijia Medical Announces Successful Completion of Patient Enrollment for Pivotal TaurusTrio Transcatheter Aortic Regurgitation Clinical Trial

More Unpleasant Surprises Could Be In Store For Peijia Medical Limited's (HKG:9996) Shares After Tumbling 29%

Estimating The Intrinsic Value Of Peijia Medical Limited (HKG:9996)

Does Peijia Medical (HKG:9996) Have A Healthy Balance Sheet?

Forecast to breakeven in 2025

First half 2023 earnings released: CN¥0.31 loss per share (vs CN¥0.14 loss in 1H 2022)

Peijia Medical Limited to Report First Half, 2023 Results on Aug 31, 2023

Now 22% undervalued after recent price drop

Calculating The Fair Value Of Peijia Medical Limited (HKG:9996)

Peijia Medical Limited Announces First Patient in Multi-Center Registration Clinical Trial of Taurustrio™? Transcatheter Aortic Valve Replacement System in China

Peijia Medical Limited Provides Unaudited Revenue Guidance for the Period from January 1, 2023 to June 30, 2023

New minor risk - Profitability

Peijia Medical Limited Receives Approval from the National Medical Products Administration of the PRC for the Registration Application of DCwireTM Micro Guidewire

Is Peijia Medical (HKG:9996) A Risky Investment?

Getting In Cheap On Peijia Medical Limited (HKG:9996) Is Unlikely

Executive Director & Company Secretary recently sold HK$3.1m worth of stock

Forecast to breakeven in 2025

Consensus EPS estimates fall by 73%

Are Investors Undervaluing Peijia Medical Limited (HKG:9996) By 40%?

Peijia Medical Limited Announces First Patient Enrollment in the Multi-Center Registration Clinical Trial of Geminione Transcatheter Edge-To-Edge Repair System in China

Peijia Medical Limited Announces in Partnership with inQB8 Medical Technologies, LLC Successfully Completed the First Patient Implant in the First-In-Man Clinical Trial of the MonarQ Transcatheter Tricuspid Valve Replacement System in the World

Less than half of directors are independent

Peijia Medical Limited Announces First Patient Implant in Multi-Center Registrationclinical Trial of Peijia Highlife Transcatheter Mitralvalve Replacement System in China

Despite Lacking Profits Peijia Medical (HKG:9996) Seems To Be On Top Of Its Debt

A Look At The Fair Value Of Peijia Medical Limited (HKG:9996)

First half 2022 earnings released: CN¥0.14 loss per share (vs CN¥0.27 loss in 1H 2021)

Peijia Medical Limited to Report First Half, 2022 Results on Aug 19, 2022

Forecast to breakeven in 2024

Peijia Medical Limited Announces Executive Changes

Peijia Medical Limited Receives NMPA Approval for Registration Application of Fluxcap Balloon Guide Catheter

Peijia Medical Limited Receives the Approval from the National Medical Products Administration of the PRC for the Registration Application of Tethys AS Aspiration Catheter

Peijia Medical Limited, Annual General Meeting, Jun 10, 2022

Full year 2021 earnings: EPS misses analyst expectations

Less than half of directors are independent

Full year 2021 earnings: EPS exceeds analyst expectations

Peijia Medical Limited to Report Fiscal Year 2021 Results on Mar 31, 2022

We're Hopeful That Peijia Medical (HKG:9996) Will Use Its Cash Wisely

Peijia Medical Limited Receives the Approval from the National Medical Products Administration for Syphonet® Stent Retriever

Peijia Medical Limited Announces First Patient Implant in Research Clinical Trial of Peijia's Highlife Trans-Septal Mitral Valve Replacement System in China

We Think Peijia Medical (HKG:9996) Can Easily Afford To Drive Business Growth

Peijia Medical Announces First Patient Implant in the Clinical Trial of Its Third-Generation Transcatheter Aortic Valve System TaurusNXT

Peijia Medical Limited Announces First Patient Implant in Clinical Trial of TaurusNXT

First half 2021 earnings released: CN¥0.27 loss per share (vs CN¥8.68 loss in 1H 2020)

We're Hopeful That Peijia Medical (HKG:9996) Will Use Its Cash Wisely

Peijia Medical Limited Receives the Approval from the National Medical Products Administration of the PRC of the Registration Application for TaurusElite

Is Peijia Medical Limited (HKG:9996) Worth HK$28.3 Based On Its Intrinsic Value?

Full year 2020 earnings released: CN¥4.43 loss per share (vs CN¥2.33 loss in FY 2019)

Full year 2020 earnings released: CN¥4.43 loss per share (vs CN¥2.26 loss in FY 2019)

Peijia Medical Limited to Report Fiscal Year 2020 Results on Mar 29, 2021

Could The Peijia Medical Limited (HKG:9996) Ownership Structure Tell Us Something Useful?

Peijia Medical Limited Announces Patient Enrollment for the Clinical Trial Ofshenyi Stent Retriever

Peijia Medical Limited's (HKG:9996) Intrinsic Value Is Potentially 43% Above Its Share Price

New 90-day high: HK$31.55

We Think Peijia Medical (HKG:9996) Can Afford To Drive Business Growth